Seattle doctor developing treatment for sickest COVID-19 patients

SEATTLE — The fatality rate for COVID-19 victims on ventilators has been 50% or higher.

So, at Atossa Therapeutics in Seattle, Dr. Steven Quay is getting a drug combination ready for a clinical trial in a hard-hit hospital back east.

“There’s a side port on the ventilator where you can put medication for these patients … basically they can breathe a mist while they are on the ventilator and the goal is to get them off the ventilator and once you are off the ventilator you’ll have an improved clinical course.

Quay is CEO of Seattle’s Atossa Therapeutics. He’s says he’s invented seven FDA approved drugs for other illnesses.

Called H-NAC, the drug would put a coating over the parts of the virus that help them replicate so quickly, rendering it ineffective, similar to what a vaccine does.

“We want to teach the immune system to coat the virus with antibodies, I’m coating the virus … with these two already FDA approved drugs,” he said.


Share on facebook
Share on twitter
Share on linkedin
Share on pinterest

About Dr. Quay

Steven Quay is the CEO of Atossa Therapeutics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics for breast cancer and COVID-19. He received his M.D. and Ph.D. from The University of Michigan, was a postdoctoral fellow in the Chemistry Department at MIT with Nobel Laureate H. Gobind Khorana, a resident at the Harvard-MGH Hospital, and spent almost a decade on the faculty of Stanford University School of Medicine. A TEDx talk he delivered on breast cancer prevention has been viewed over 200,000 times. His 300+ contributions to medicine have been cited over 9,900 times, placing him in the top 1% of scientists worldwide. He holds 87 US patents and has invented seven FDA-approved pharmaceuticals which have helped over 80 million people.

The COVID-19 HOPE Clinical Trial​